Vanda (VNDA) - מקדם חוב לטווח ארוך להון

Vanda Pharmaceuticals (VNDA) develops unique treatments for insomnia and schizophrenia, creating sustainable demand through lifelong therapy courses. The company generates revenue from government fund payments and insurance reimbursements for its drugs Hetlioz and Fanapt. This price trend chart shows that the metric is 0.09. Stable cash flow from proven products ensures reliable capital protection, and patent risks are already priced in.

This indicator measures the proportion of long-term liabilities within the equity structure, allowing for an assessment of financial independence and the balance sheet's resilience to interest rate risks. By analyzing the history of long-term debt-to-equity load, an investor can determine how effectively Vanda Pharmaceuticals (VNDA) utilizes borrowed funds to protect its monopoly positions in the rare psychotropic drug market.